Kindred Biosciences (KIN) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Kindred Biosciences Announces Fourth Quarter and Year-End 2014 Financial Results
March 12, 2015 4:01 PM EDTSAN FRANCISCO, March 12, 2015 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended December 31, 2014. Â
Conference Call and Webcast at 4:30 p.m. Eastern / 1:30 p.m. Pacific Â
KindredBio today announced its fourth quarter financial results and provided updates on its programs.
Development Updates
KindredBio continues to build and advance its pipeline, including biologics, and now has over 20 programs across multiple product candidates and indications. Some of the key programs are highlighted below.
The pivotal field trial of SentiKind, a KCNQ potassium... More
